Trials / Completed
CompletedNCT02413281
A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
A Phase 1, Single-Dose, Double-Blind, Placebo-and Active-Controlled, Randomized, 6-way Crossover Human Abuse Liability Evaluation of ALKS 5461
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the abuse potential of ALKS 5461.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALKS 5461 | Sublingual tablets, single administration |
| DRUG | Buprenorphine | Sublingual tablets, single administration |
| DRUG | Placebo | Sublingual tablets, single administration |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2015-04-09
- Last updated
- 2015-11-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02413281. Inclusion in this directory is not an endorsement.